

## **Essentials of Systemic Cancer Therapies for the Oncology Nurse**

### **Presented by**

Joaquin Buitrago, PhD, RN, OCN, Lisa Green, MSN, NPD-BC, AOCN, Meghan Jones, MSN, RN, OCN, Katherine Mishaw, MS, AOCN, OCN, RN-BC, Tiffany Tolden, MSN, Bindu Varghese, MSN, RN, OCN, PCCN, Stela Dike, MSN, OCN, Mildred A Toth, MS, AOCN, Annamma Varghese, DNP, RN, OCN

**Wednesday, 12/15/2021 8:00**

**Virtual**

### **Target Audience:**

Specialties: General Oncology  
Professions: Nurse/APN, Other

### **Description:**

Enable oncology nurses to apply informational resources and guidelines for knowledgeable and safe administration of systemic cancer therapies and apply evidence based nursing care interventions (including patient education), to prevent, minimize, and/or manage associated adverse effects. Day 1 will be virtual (Zoom) and Day 2 will be on-site R11.1400 (Hickey Auditorium) Requirements for Successful Completion of Program: • Register • Attend entire learning activity • Successfully pass post test with minimal score of 80% • Complete evaluation within 7 days

### **Learning Outcomes:**

- 1 State principles guiding systemic cancer therapies (standard regimens and clinical trials) and response, based upon a basic understanding of carcinogenesis.
- 2 Address the continuum of care during the cancer journey for various patient populations
- 3 Discuss phases of clinical trials and the nurse's role.
- 4 Discuss how systemic treatments for cancer work (chemotherapy, hormone therapy, molecular targeted therapy and immunotherapy), including principles guiding cancer therapy and effects on cell proliferation.
- 5 Describe classifications and associated side effects of chemotherapy, hormone therapy, molecular targeted therapy and immunotherapy.
- 6 Articulate nursing standards and available resources that address nursing practice for safe administration of systemic cancer therapies, including patient education.
- 7 Discuss the process of safe administration of antineoplastic agents, including accurate calculation of body surface area (BSA) and dosing
- 8 Describe safety implications for the various administration routes of systemic cancer therapies.
- 9 Describe safe handling practices when managing hazardous drugs, including patient management, personal protective equipment (PPE) and spill management.
- 10 Identify prevention, recognition and management measures of local site reactions associated with vesicant extravasation, irritation and flare reactions.
- 11 Identify prevention, recognition and management of systemic reactions associated with drug administration including hypersensitivity, anaphylaxis and cytokine-release syndrome.
- 12 Identify critical assessment parameters and nursing interventions for myelosuppression caused by systemic cancer therapies.
- 13 Describe incidence, risk factors, assessment and interventions for management of systemic cancer therapy induced nausea and vomiting.
- 14 Discuss potential sexual and reproductive concerns for patients who receive cancer treatments, including assessment, communication and management strategies.
- 15 Discuss ethical and legal issues that nurses may face when administering systemic cancer therapies, incorporating standards, laws, and position statements as guides.
- 16 Apply principles, resources and standards to describe steps in pre-treatment preparation and verification, including review of treatment plans, orders, dose calculations and patient education in discussion exemplars.
- 17 Apply principles, resources, standards and evidence-based nursing care interventions to prevent, minimize or manage side effects and toxicities of combination systemic cancer therapies across the cancer care continuum.

**Accreditation:**

The University of Texas MD Anderson Cancer Center is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

**Credit Designation:'**

The University of Texas MD Anderson Cancer Center designates this live activity will award 15.08 Nursing Continuing Professional Development (NCPD) credits which includes APRN 5.40 Pharmacotherapeutics credit(s).

**Commercial Support:**

No commercial support has been received for this activity.

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

**Faculty & Planner Disclosure:**

Name of individual	Individual's role in activity	Name of commercial interest/Nature of relationship
Priscilla Marsh	Activity Administrator	Nothing to disclose - 11/01/2021
Joaquin Buitrago, PhD, RN, OCN	Faculty	Nothing to disclose - 04/28/2021
Lisa Green, MSN, NPD-BC, AOCN	Faculty	Nothing to disclose - 10/14/2021
Meghan Jones, MSN, RN, OCN	Faculty	Nothing to disclose - 11/18/2021
Katherine Mishaw, MS, AOCN, OCN, RN-BC	Faculty	Nothing to disclose - 10/09/2021
Tiffany Tolden, MSN	Faculty	Nothing to disclose - 10/11/2021
Bindu S Varghese, MSN, RN,OCN,PCCN	Faculty	Nothing to disclose - 04/12/2021
Stella Dike, MSN, OCN	Faculty, Nurse Planner	Nothing to disclose - 02/01/2021
Mildred A. Toth, MS, Advanced Oncology Certified Nurse (AOCN)	Faculty, Nurse Planner	Nothing to disclose - 09/21/2021
Annamma Varghese, DNP, RN, OCN	Faculty	Nothing to disclose – 11/16/2021